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In human cirrhosis, adrenergic hyperfunction causes proximal tubular fluid retention and
contributes to diuretic-resistant ascites, and clonidine, a sympatholytic drug, improves natri-
uresis in difficult-to-treat ascites.
Aim
To compare clonidine (aspecific α2-adrenoceptor agonist) to SSP-002021R (prodrug of
guanfacine, specific α2A-receptor agonist), both associated with diuretics, in experimental
cirrhotic ascites.
Methods and Results
Six groups of 12 rats were studied: controls (G1); controls receiving furosemide and potas-
sium canrenoate (G2); rats with ascitic cirrhosis due to 14-week CCl4 treatment (G3); cir-
rhotic rats treated (over the 11th-14th CCl4 weeks) with furosemide and canrenoate (G4),
furosemide, canrenoate and clonidine (G5), or diuretics and SSP002021R (G6). Three rats
of each group had their hormonal status and renal function assessed at the end of 11th,
12th, 13th, and 14th weeks of respective treatments.Cirrhotic rats in G3 and G4 gained
weight over the 12th-14th CCl4 weeks. In G4, brief increase in sodium excretion over the
11th-12th weeks preceded worsening of inulin clearance and natriuresis (diuretic resis-
tance). In comparison with G4, the addition of clonidine (G5) or guanfacine (G6) to diuretics
improved, respectively, sodium excretion over the 11th-12th CCl4 weeks, or GFR and elec-
trolytes excretion over the 13th-14th CCl4 weeks. Natriuretic responses in G5 and G6 were
accompanied by reduced catecholamine serum levels.
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Conclusions
α2A-receptor agonists restore glomerular filtration rate and natriuresis, and delay diuretic-
resistant ascites in experimental advanced cirrhosis. Clonidine ameliorates diuretic-depen-
dent natriuresis just for a short time.
Introduction
Refractory ascites, which occurs in most cirrhotic patients with end-stage liver disease and avid
sodium retention, comprises diuretic-intractable and diuretic-resistant ascites [1]. In order to
treat the latter, which is genuinely unresponsive to the use of diuretics, several therapies have
been tested, including repeated paracentesis with intravenous albumin, peritoneal venous
shunt, and transjugular intrahepatic portosystemic shunt (TIPS), but none of these procedures
was found to improve survival in patients with advanced liver cirrhosis [2, 3]. TIPS may even
precipitate hepatic failure and worsen survival rate in patients with high Child-Pugh score [4].
The mechanisms of diuretic-resistant ascites, whose essential clinical features are progres-
sive increase in body weight and decrease in natriuresis despite doses of diuretics that were
previously achieving a diuresis, are manifold: peripheral arterial vasodilatation, portal hyper-
tension, reduction of the effective arterial blood volume, and permanent activation of endoge-
nous anti-natriuretic and renal vasoconstrictor mechanisms (renin-angiotensin [RAS] and
sympathetic nervous [SNS] systems, non-osmotic hypersecretion of vasopressin [ADH]) [5, 6].
Diuretic-resistant ascites occurs as a result of extreme vascular underfilling with maximal acti-
vation of these anti-natriuretic systems [1]. Specifically, the activated SNS and RAS stimulate
kidney arterial vasoconstriction, which eventually leads to decrease in renal blood flow and glo-
merular filtration rate. Additionally, norepinephrine and angiotensin II increase reabsorption
of sodium in the proximal renal tubule, which leads to negligible response to diuretics and to
enhanced secretion of renin [7].
In patients with cirrhosis and diuretic-resistant ascites, clonidine, an α2-adrenoceptor ago-
nist that decreases central sympathetic outflow, release of norepinephrine from vascular neu-
roeffector junctions [8] and portal pressure [9], has been tried as adjunct to common diuretics
with promising results. Clonidine, associated with the α1-adrenoceptor agonist midodrine and
standard medical therapy (SMT), was superior to SMT alone in the control of ascites in cir-
rhotic patients [10]. Moreover, clonidine improved the effects of diuretics (spironolactone
alone or the combination of furosemide and spironolactone) in patients with advanced liver
cirrhosis and ascites [11, 12].
Clonidine’s binding affinity does not differ appreciably among the many α2-receptors so far
described. Indeed, five α2-receptors subtypes exist: α2A, α2B1, α2B2, α2C, and α2D, which belong
to the group A of rhodopsin-like G protein-coupled receptor class [13]. Clonidine systemic
effects do not depend preferentially on stimulation of α2-receptors that are pre- or post-junc-
tional (i.e. pre- or post-synaptic), located either in the central nervous system, in the wall of
peripheral blood vessels, or in the kidney [13, 14].
The similar affinity of clonidine for this multitude of α2-adrenoceptors is a manifest draw-
back and may render the results of clonidine itself sub-optimal in the treatment of the ascitic
patients that are ill-responsive to diuretics. Indeed, clonidine, through stimulation of endothe-
lial α2D-receptors, may enhance vascular production of nitric oxide (NO), leading to arterial
vasodilatation, hypotension [14] and worsening of the hyperdynamic circulation of cirrhotic
patients. Furthermore, enhanced NO synthesis increases the expression of apical Na+-K+-2Cl-
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cotransporters in the loop of Henle, and therefore renal sodium retention [15]. Finally, stimula-
tion of α2B-adrenoceptors, located in the basolateral membrane of the proximal renal tubule
[16], leads to accelerated sodium reabsorption even in this nephron segment [16, 17].
Guanfacine, a different α2-adrenoceptor agonist, has approximately 60-fold more selectivity
for α2A-receptors than clonidine [18] and does not lower arterial blood pressure significantly
in patients with arterial hypertension [19]. Guanfacine, through specific stimulation of renal
α2A-adrenoceptors, increases osmolar clearance and sodium excretion in a peculiar naltrexone
(opioid receptor antagonist)-sensitive manner, according to the established natriuretic function
of renal α2A-adrenoceptors [18]. The rat kidney contains α2A-receptors, which are located in
the inner stripe of the renal cortex and in the outer medulla [16, 20, 21], where stimulation of
these post-synaptic receptors antagonizes the antidiuretic effects of ADH [22]. Indeed, guanfa-
cine leads to significant aquaretic effects even in experimental ascitic cirrhosis [23]. For these
reasons, guanfacine may represent a much better candidate drug, among α2-receptor agonists,
than clonidine in order to blunt adrenergic hyperfunction and restore diuretic efficiency in
advanced cirrhotic ascites.
With this premise in mind, the present study has been designed to achieve two major aims:
a) to characterize, in terms of renal function and hormonal status, the occurrence and identify
the timing of unresponsiveness to traditional diuretic therapy in the experimental model of rats
with advanced carbon tetrachloride (CCl4)-dependent cirrhosis; b) to investigate in such a stage
of experimental decompensated cirrhosis the hypothesized advantage of guanfacine over cloni-
dine, when these drugs are added to diuretics in order to restore their natriuretic efficiency.
Materials and Methods
Studies were performed on 48 male adult Wistar rats with advanced liver cirrhosis and 24 male
adult Wistar control rats. All Wistar rats were provided by Harlan Italy, Udine, Italy. Both cir-
rhotic and control groups were fed with standardized chow and water. Cirrhosis was induced
by CCl4 (Riedel-de Haën, Sigma-Aldrich, Seelze, Germany) administered by gavage twice
weekly for 14 weeks [24]. The pathophysiological progression of this experimental model is
highly predictable and reproducible: after 9 weeks, micronodular cirrhosis is evident, rats are
devoid of ascites (as assessed by laparotomy) and portal pressure is increased to about 10
mmHg; after 11 weeks, rats present ascites and their mean portal pressure is 24 mmHg; after
14 weeks cirrhotic rats develop renal failure and eventually die [25, 26]. Control rats were stud-
ied after 14 weeks of standardized diet. Rats were cared for in compliance with the European
Council directives (No. 86/609/EEC) and with the Principles of Laboratory Animal Care (NIH
no. 85–23, revised in 1985). This scientific project was approved by the Ethical Committee of
the University of Torino (permit number: D.M. 92/2010-B). In this study, the following active
drugs were administered to the rats according to the protocol described in the next paragraphs:
furosemide, Henle’s loop diuretic (Sanofi-Aventis, Milano, Italy); potassium canrenoate, aldo-
sterone receptor antagonist (Teofarma, Pavia, Italy); clonidine, α2-adrenoceptor agonist (Boeh-
ringer Ingelheim, Milano, Italy). Finally, SSP-002021R, oral prodrug of guanfacine, selective
α2A-adrenoceptor agonist, was provided by Shire, Basingstoke, U.K.
Animal groups
Furosemide, canrenoate, clonidine, and SSP-002021R were dissolved in distilled water to
obtain different solutions to be administered orally to the rats in 400 μl of fluid. The animals
were divided into six groups of twelve rats: controls receiving no intervention (group G1);
controls receiving three times a week for 4 weeks oral furosemide (0.5 mg/Kg b.w.) and oral
potassium canrenoate (2 mg/Kg b.w.) (G2); rats with ascitic cirrhosis due to 14-week CCl4
Guanfacine and Cirrhotic Ascites
PLOS ONE | DOI:10.1371/journal.pone.0158486 July 6, 2016 3 / 13
administration and receiving no active drug (G3); cirrhotic rats treated with oral furosemide
(0.5 mg/Kg b.w. three times a week) plus oral potassium canrenoate (2 mg/Kg b.w. three times
a week) between the beginning of the 11th and the end of the 14th week of CCl4 (G4); cirrhotic
rats treated with oral furosemide, oral potassium canrenoate (see above dosage), and oral cloni-
dine (0.3 mcg three times a week) between the beginning of the 11th and the end of the 14th
week of CCl4 (G5); cirrhotic rats treated with oral furosemide, oral canrenoate, and the oral
prodrug of guanfacine (SSP002021R, selective α2A-adrenoceptor agonist, 5 mg/kg b.w. three
times a week) between the beginning of the 11th and the end of the 14th week of CCl4 (G6).
Dosage of furosemide and potassium canrenoate was patterned on respective standard daily
human dosage. A dosage of clonidine 0.3 mcg on alternate days was chosen: previous experi-
ments in this laboratory showed clonidine 0.5 mcg caused arterial hypotension in cirrhotic rats
and blunted further the effects of diuretics (unpublished data), and published papers showed
the effectiveness of low, non-hypotensive doses of clonidine (75 mcg once or twice daily in
adult human cirrhotic patients) [10–12]. The dosage of SSP002021R used in this study was
established by the provider of the drug (Shire, Basingstoke, U.K.)
Study protocol
Rats belonging to G1–G6 were weighed, studied and finally sacrificed, three at a time, at the
end of weeks 11, 12, 13, and 14 of observation or CCl4 administration, with or without the
above active treatments. All rats treated with active drugs were studied within 8 hours after the
latest drug administration. Each day of study, rats were anesthetized with a mixture of Ketavet
100 (Farmaceutici Gellini, Sabaudia, Italy) and Rompum (Xylazine, Bayer A.G., Leverkusen,
Germany) (4:1 v:v) by intraperitoneal injection (0.5 ml mixture/200 g b. wt.) [27]; laparotomy
was performed and the urinary bladder was emptied before clamping the urethral orifice for
further urine collection. Shortly thereafter, inulin (IN) 10% (w/v) (Laevosan-Gesellschaft, Linz/
Donau, Austria) plus para-aminohippurate (PAH) 20% (w/v) (Nephrotest, BAG Gmbh,
Munich, Germany) were administered into the caudal vein as a priming bolus followed by a
continuous infusion, in order to assess glomerular filtration rate (GFR) and renal plasma flow
(RPF) by means of their respective steady-state plasma clearances (CIN and CPAH) [28, 29].
When 90 minutes of IN and PAH infusion had elapsed (i.e. once their steady-state plasma con-
centrations had been reached), cardiac blood was sampled to assess plasma osmolality and con-
centrations of inulin, PAH, sodium, and potassium. Blood samples withdrawn at this time
were also used to measure plasma renin activity (PRA) and concentrations of vasopressin
(ADH), aldosterone (A), epinephrine (E), and norepinephrine (N). Finally, urinary bladder
was emptied to collect the urine volume produced during the 90 min of IN and PAH venous
infusion. This urine was used to determine its osmolality and the excretion of sodium and
potassium. Rats were then killed by exsanguination through the aorta. Anesthetized rats in
each group had their mean arterial pressure evaluated through tail sphygmomanometry, as
described elsewhere [25], before performing laparotomy.
Plasma and urine analyses
Plasma and urinary concentrations of electrolytes and IN and PAH plasma concentrations
were measured as described elsewhere [26, 30, 31]. Plasma A, ADH, N, E, and PRA were deter-
mined according to standard procedures [25, 32].
Calculations
Sodium and potassium clearances (CNa and CK) were calculated through the usual formula
[32]. Inulin clearance (CIN) and para-aminohippurate clearance (CPAH) were calculated
Guanfacine and Cirrhotic Ascites
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through the steady-state plasma clearance formula as:
Cx ¼ Infusion rate ðxÞ=ssP‐x
where ssP-x is the steady-state plasma concentration of x. CIN and CPAH were taken as mea-
sures of GFR and RPF, respectively [28, 29]. Filtration fraction (FF) and filtered sodium load
(FlNa) were calculated through the usual formulae [32].
Fractional sodium excretion (FENa) and fractional potassium excretion (FEK) were also cal-
culated [27].
Tubular free-water reabsorption (TF-WR) was calculated, following Rose and Post [33],
through the formula:
TF‐WR ¼ Cosm V
where V is the urinary output (ml/min) and Cosm is the osmolar clearance, which was com-
puted via the usual formula:
Cosm ¼ ðUosm VÞ=Posm
where Uosm and Posm are urine and plasma osmolarities, respectively.
Mean arterial pressure (MAP) was calculated from the formula:
1=3ðsystolic blood pressure  diastolic blood pressureÞ þ diastolic blood pressure
Statistical analysis
Statistical comparisons of renal function or hormone levels in rats belonging to different G1–
G6 groups, performed after definite times of exposure to CCl4, were made by one-way analysis
of variance (ANOVA) followed by Tukey’s LSD post-hoc comparisons. Comparisons among
rats belonging to the same group, but studied at different times (i.e. measurements of
mean ± SD of weeks 11–12 vs. weeks 13–14 of observation or CCl4) were made through one-
tailed Wilcoxon rank sum test for unpaired data. All results are expressed as means ± SD. Sig-
nificance is accepted at the 5% probability level.
Results
Identification of unresponsiveness to diuretics in rats with experimental
ascitic cirrhosis
Normal rats (G2) had a progressive increase in urine volume and sodium excretion without
derangement of renal function over the four weeks of diuretic treatment (Table 1). The body
weight of G3 and G4 cirrhotic rats increased progressively over the 12th-14th weeks of CCl4
due to ascites accumulation, irrespective of standard dosage of diuretics in G4 (Table 1, Fig 1).
From the end of week 12 onwards, in G4 the occurrence of unresponsiveness to diuretics was
characterized by values of GFR, renal plasma flow, sodium excretion even lower (Table 1), and
systemic catecholamine levels even higher than in cirrhotic rats not treated with diuretics (G3)
(Figs 2 and 3). This means that overt diuretic-resistant ascites in this model of advanced cirrho-
sis occurs at the end of 12 weeks of CCl4.
Renal function
In cirrhotic rats, the favourable effects of clonidine, when added to furosemide and canrenoate
(G5), was prompt and resulted in an increase in urine flow rate and sodium excretion that
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paralleled and expanded the slight one due to diuretics only in G4 (Table 1, Fig 2). Nonetheless,
the advantage of treatment with clonidine was also transient and followed by accelerated
derangement of renal function over weeks 13–14 (Tables 1 and 2; Fig 2). Guanfacine was
slower that clonidine in achieving an increase in diuresis and natriuresis, but its effects were
progressive and significant mostly on weeks 13–14 of CCl4 (Table 1, Fig 2). Actually, guanfa-
cine, added to diuretics, caused a progressive improvement in renal function (GFR and RPF)
over the four weeks of observation (weeks 11–14) (Table 1). Guanfacine, when added to the
Table 1. Renal function. Comparisons between means ± SD of GFR, RPF, urine volume, urine sodium excretion rate, etc. taken on weeks 11–12 (Group
GXA) vs. weeks 13–14 (Group GXB) or among different G1–G6 groups. In each group, worsening of clinical parameters underlined, improvements in bold
print (weeks 13–14, Group GXB, vs. weeks 11–12, Group GXA).
Body weight (g) CIN (ml/min) CPAH (ml/min) FF (%) Urine volume (ml/h) Natriuresis (μmol/h)
Group G1A 407 ± 53 2.1 ± 0.19 4.5 ± 0.8 46 ± 6 0.72 ± 0.07 94 ± 14
G1B 400 ± 46 2.3 ± 0.26 4.07 ± 0.81 56 ±10 0.69 ± 0.07 91 ± 18
G2A 401± 48 2 ± 0.13 4.13 ± 0.73 48 ± 8 0.69 ± 0.08 94 ± 12
G2B 377 ± 36 2.15 ± 0.2 4.6 ± 0.93 46 ± 6 0.91 ± 0.09* 121 ± 12*
G3A 320 ± 18 1.68 ± 0.13 3.6 ± 0.64 52 ± 7 0.325 ± 0.04 19.5 ± 5
G3B 340 ± 12* 1.44 ± 0.13 2.5 ± 0.21* 50 ± 7 0.315 ± 0.04* 21 ± 3
G4A 312 ± 11 1.7 ± 0.12 3.2 ± 0.45 56 ± 8 0.54 ± 0.06 65 ± 6
Ψ
G4B 340 ± 12* 1.2 ± 0.11*
Ψ 2.1 ± 0.14*Ψ 57 ±7 0.28 ± 0.02* 15.5 ± 2*Ψ
G5A 295 ± 7 2.0 ± 0.12
¥ 3.9 ± 0.18¥ 74 ± 8 1.015 ± 0.06¥ 157.5 ± 16¥
G5B 328 ± 7* 1.2 ± 0.21* 3.57 ±0.85 47 ± 6* 0.205 ± 0.03* 18 ± 3*
G6A 333 ± 12 1.5 ± 0.11 3.61 ± 0.25 38 ± 5 0.34 ± 0.06 17.5 ± 6
G6B 306 ± 11*
Ψ 2.1 ± 0.19*Ψ 4.01 ± 0.21*Ψ 52 ± 6* 0.90 ± 0.07*Ψ 85 ± 14*Ψ
Data are means ± SD.
*P<0.05 versus respective GXA;
ΨP<0.05 versus G3B;
¥P<0.05 versus G4A.
Statistical comparisons of renal function or hormone levels in rats belonging to different G1–G6 groups, performed after definite times of exposure to CCl4,
were made by one-way analysis of variance (ANOVA) followed by Tukey’s LSD post-hoc comparisons. Comparisons among rats belonging to the same
group, but studied at different times (i.e. measurements of mean ± SD of weeks 11–12 vs. weeks 13–14 of observation or CCl4) were made through one-
tailed Wilcoxon rank sum test for unpaired data.
CIN: steady-state plasma clearance of inulin; CPAH: steady-state plasma clearance of para-aminohippurate; FF: filtration fraction.
doi:10.1371/journal.pone.0158486.t001
Fig 1. Progressive weight gain of untreated cirrhotic rats (G3, red line) and of cirrhotic rats treated
with diuretics (G4, yellow line) or with diuretics plus clonidine (G5, blue line). Further groups depicted:
G1 (healthy controls, black line), G6 (cirrhotic rats treated with diuretics plus oral prodrug of guanfacine,
green line). Mean measurements ± SD of three rats studied at a time in each group are depicted.
doi:10.1371/journal.pone.0158486.g001
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traditional diuretic treatment of ascites over weeks 11–14, caused a steady and progressive
increase in urinary potassium excretion rate (Table 2). Guanfacine, at the used dosage and
associated with diuretics, did not affect significantly tubular free-water reabsorption. Notably,
in cirrhotic rats treated with diuretics alone (G4) or with diuretics plus clonidine (G5), severe
Fig 2. Transient natriuretic effects in G4 (cirrhotic rats treated with furosemide and potassium
canrenoate, yellow line) and G5 (cirrhotic rats treated with diuretics plus clonidine, blue line) over
CCl4 weeks 11–12. Progressive natriuretic effects in G6 (cirrhotic rats treated with diuretics plus oral prodrug
of guanfacine, green line). Further groups depicted: G1 (healthy controls, black line), G3 (untreated cirrhotic
rats, red line). Mean measurements ± SD of three rats studied at a time in each group are depicted.
doi:10.1371/journal.pone.0158486.g002
Fig 3. Graphical depiction of adrenergic hypertone in cirrhotic rats, treated (G4) or not (G3) with diuretics. Early (G5) and late
(G6) blunting of adrenergic function in cirrhotic rats receiving, respectively, clonidine or guanfacine, along with diuretics.
doi:10.1371/journal.pone.0158486.g003
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GFR deterioration occurred during the 13th and 14th weeks of CCl4 (Table 1). In these two
groups, which had their sodium excretion rates transiently increased over the first two weeks of
respective treatment, different mechanisms might have led to similar anti-natriuretic effects in
the long run: clonidine promptly increases GFR and natriuresis (Table 1 and Fig 2), which are
then followed by later deterioration of renal function; diuretics cause an immediate tubular
diuretic effect that leads to decrease in effective arterial blood volume and earlier deterioration
of GFR due to urinary fluid loss not counterbalanced by any sympatholytic action (Tables 1
and 3; Figs 2 and 3).
Hormonal status (Table 3)
α2-adrenergic agonists blunted the adrenergic hyperfunction that characterizes advanced
liver cirrhosis, as shown by reduced levels of serum norepinephrine in ascitic cirrhotic rats
treated with clonidine (G5) or guanfacine (G6) plus diuretics compared to cirrhotic rats
untreated (G3) or treated with sole diuretics (G4). When the behaviour of epinephrine serum
levels is considered (Fig 3), blunting of adrenergic function was early and transient with clo-
nidine and, instead, progressive and long-lasting with guanfacine. The effect of guanfacine
on adrenergic function contributes to the increased natriuretic effects and the amelioration
of GFR described previously. In the advanced stage of liver disease, cirrhotic rats (G3)
showed a progressive and severe hyper-reninism (i.e. secondary aldosteronism), which was
maximal during overt refractory ascites (i.e. on CCl4 weeks 13 and 14) (Fig 4). As expected,
even this phenomenon was positively affected by the blunting of adrenergic function caused
by α2-agonists (Fig 3).
Table 2. Renal function. Comparisons between means ± SD of FENa, kaliuresis, plasma Na, etc. taken on weeks 11–12 (Group GXA) vs. weeks 13–14
(Group GXB) or among different G1–G6 groups. In each group, worsening of clinical parameters underlined, improvements in bold print (weeks 13–14,
Group GXB, vs. weeks 11–12, Group GXA).
FENa (%) Kaliuresis μmol/h) Plasma Na (mEq/l) Plasma K (mEq/l) Cosm (ml/h) TF-WR (ml/h)
Group G1A 2.2 ± 0.13 31 ± 5 141 ± 2 4.1 ± 0.6 1.9 ± 0.22 1.18 ± 0.14
G1B 2.1 ± 0.12 34 ± 6 139 ± 4 3.8 ± 0.8 1.92 ± 0.21 1.23 ± 0.22
G2A 2.2 ± 0.2 47 ± 6 141 ± 3 4.4 ± 1.1 1.93 ± 0.27 1.24 ± 0.25
G2B 3.5 ± 0.22* 47 ± 8 137 ± 2 3.6 ± 2.1 2.02 ± 0.51 1.11 ± 0.11
G3A 1.6 ± 0.27 47.5 ± 9 135 ± 3 3.5 ± 1.4 1.47 ± 0.33 1.15 ± 0.20
G3B 1.2 ± 0.19 40 ± 14 136 ± 2 3.2 ± 0.8 1.01 ± .036 0.7 ± 0.21
G4A 2.1 ± 0.47 80 ± 16 137 ± 4 3.6 ± 1.1 1.77 ± 0.33 1.2 ± 0.22
G4B 0.7± 0.19*
Ψ 40 ± 10* 132 ± 3 3.1 ± 0.9 1.01 ± 0.26* 0.7 ± 0.26
G5A 2.3 ± 0.4 90 ± 17 139 ± 3 3.1 ± 0.8 2.56 ± 0.72 1.75 ± 0.38
G5B 1.1 ± 0.29* 15 ± 7* 135 ± 3 3.8 ± 0.9 0.455 ± 0.06* 0.25 ± ± 0.06*
G6A 1.3 ± 0.32 50 ± 14 141 ± 2 3.7 ± 0.4 1.04 ± 0.27 0.7 ± 0.2
G6B 2.8 ± 0.6*
Ψ 97 ± 19*Ψ 136 ± 2* 3.0 ± 0.3* 1.85 ± 0.4* 0.95 ± 0.22
Data are means ± SD.
*P<0.05 versus respective GXA;
ΨP<0.05 versus G3B.
Statistical comparisons of renal function or hormone levels in rats belonging to different G1–G6 groups, performed after definite times of exposure to CCl4,
were made by one-way analysis of variance (ANOVA) followed by Tukey’s LSD post-hoc comparisons. Comparisons among rats belonging to the same
group, but studied at different times (i.e. measurements of mean ± SD of weeks 11–12 vs. weeks 13–14 of observation or CCl4) were made through one-
tailed Wilcoxon rank sum test for unpaired data.
Cosm: osmolar clearance; FENa: fractional sodium excretion; TF-WR, tubular free-water reabsorption.
doi:10.1371/journal.pone.0158486.t002
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Table 3. Hormonal status. Comparisons between means ± SD of PRA, plasma aldosterone, etc. taken on weeks 11–12 (Group GXA) vs. weeks 13–14
(Group GXB) or among different G1–G6 groups. In each group, worsening of clinical parameters underlined, improvements in bold print (weeks 13–14,
Group GXB, vs. weeks 11–12, Group GXA).
PRA (ng/ml/h) Plasma A (pg/ml) Plasma N (ng/l) Plasma E (ng/l) Plasma ADH (pg/ml)
Group G1A 4.2 ± 0.7 420 ± 73 131 ± 18 0.98 ± 0.8 246 ± 27
G1B 5.0 ± 1.2 388 ± 87 98 ± 20 1.31 ± 0.2 221 ± 26
G2A 4.8 ± 1.4 499 ± 66 199 ± 20 1.42 ± 0.21 244 ± 50
G2B 5.22 ± 1.2 545 ± 64 322 ± 50* 1.99 ± 0.14 199 ± 38
G3A 9.2 ± 1 1602 ± 131 593 ± 66 4.2 ± 0.51 245 ± 79
G3B 20.0 ± 2.6* 2003 ± 167* 738 ± 80* 5.0 ± 0.32 368 ± 36*
G4A 11.22 ± 0.6
¥ 2121 ± 145¥ 832 ± 87¥ 6.22 ± 0.67¥ 300 ± 46
G4B 19.9 ± 2.1* 2560 ± 131*
Ψ 1002 ± 85*Ψ 6.50 ± 0.87 400 ± 45*
G5A 8.7 ± 0.8 1122 ± 88 200 ± 36
¥ 1.1 ± 0.21¥ 333 ± 67
G5B 9.2 ± 0.6 1245 ± 81 242 ± 30
¥ 2.5 ± 0.48*¥ 401 ± 130
G6A 8.8 ± 0.9 1006 ± 53 190 ± 22
¥ 2.3 ± 0.45¥ 287 ± 53
G6B 9.0 ± 0.8
Ψ 1187 ± 52Ψ 67 ± 14*¥ 0.9 ± 0.14*¥ 345 ± 40
Data are means ± SD.
*P<0.05 versus respective GXA;
ΨP<0.05 versus G3B;
¥P<0.05 versus G3A.
Statistical comparisons of renal function or hormone levels in rats belonging to different G1–G6 groups, performed after definite times of exposure to CCl4,
were made by one-way analysis of variance (ANOVA) followed by Tukey’s LSD post-hoc comparisons. Comparisons among rats belonging to the same
group, but studied at different times (i.e. measurements of mean ± SD of weeks 11–12 vs. weeks 13–14 of observation or CCl4) were made through one-
tailed Wilcoxon rank sum test for unpaired data.
A, aldosterone; ADH, vasopressin; E, epinephrine; N, norepinephrine; PRA, plasma renin activity.
doi:10.1371/journal.pone.0158486.t003
Fig 4. Marked increase in PRA (concurrent with development of diuretic-unresponsive ascites) over
CCL4 weeks 13–14 in cirrhotic rats (G3, untreated, red line, and G4, receiving diuretics only, yellow
line). Blunting of renin secretion in G5 (cirrhotic rats treated with diuretics plus clonidine, blue line) and G6
(cirrhotic rats treated with diuretics plus oral prodrug of guanfacine, green line). Further group depicted: G1
(untreated controls, black line). Mean measurements ± SD of three rats studied at a time in each group are
depicted.
doi:10.1371/journal.pone.0158486.g004
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Mean arterial pressure
When compared to absolute controls (G1), significantly lower values of MAP were measured
in the cirrhotic group treated with sole diuretics (G4) over CCl4 weeks 12–14 (all P<0.05)
(data not shown in tables).
Discussion
This study identifies the timing of overt unresponsiveness to diuretics in the standard model of
experimental ascitic cirrhosis due to chronic CCl4 administration [34]. This unresponsiveness
to diuretics occurs at the end of 12 weeks of CCl4, when two weeks of successful treatment with
furosemide and potassium canrenoate have elapsed.
Our assertion of the occurrence of such a resistance to diuretics is not, and could not be,
based on the accepted definition of refractory ascites, as this is diagnosed in patients with
advanced liver cirrhosis [35]. In our cirrhotic rats diuretic-unresponsive ascites occurs after 12
weeks of CCl4 because of the manifest lack of effects of traditional diuretics—effects we accu-
rately measured once a week and not daily—and because of the progressive weight gain despite
the diuretics (Table 1 and Figs 1 and 2). Diuretic-resistant ascites is preceded by significant
diuretic responses to the association of furosemide and anti-aldosterone drugs, and by
increased adrenergic function and secondary aldosteronism during such a diuretic response
(Tables 1 and 3, Figs 2, 3 and 4). Harbinger of diuretic-resistant ascites, which occurs over
weeks 13–14 of CCl4, i.e. after two weeks of diuretics, is a further increase in secondary aldoste-
ronism, representing a critical loss of effective arterial blood volume (Fig 4). This closely mim-
ics the occurrence of human diuretic-resistant ascites previously responsive to diuretics. Of
course, since we were not interested in the diagnosis of diuretic-intractable ascites in our exper-
imental model, we did not monitor the extra-renal side effects of diuretics (e.g. possible signs of
hepatic encephalopathy) that characterize diuretic-intractable ascites in cirrhotic patients [35].
Guanfacine, selective α2A-adrenoceptor agonist, when added to the traditional diuretic
treatment of ascites, apparently prevents the occurrence of diuretic-resistant ascites, at least
over the length of our study (i.e. 14 weeks of CCl4) (Fig 2). On the contrary, clonidine, aspecific
α2-adrenoceptor agonist and sympatholytic agent, just amplifies the diuretic effects of furose-
mide and potassium canrenoate in the weeks before the occurrence of diuretic resistance
(Fig 2).
Notably, guanfacine, a sympatholytic agent itself, in our cirrhotic rats caused a later attenua-
tion of catecholamine release, as assessed by the serial measurement of epinephrine and norepi-
nephrine plasma levels (Table 3, Fig 3). This is associated with blunting of renin production
(Fig 4) and progressive recovery of GFR over CCl4 weeks 13–14 (Table 1) These hormonal and
renal effects are accompanied by progressive increase in urinary excretions of sodium and
potassium, which are maximal after 4 weeks of guanfacine (i.e. on CCl4 week 14) (Tables 1, 2
and Fig 2). The concurrent increase in urinary excretion of sodium and potassium (Tables 1
and 2) may suggest some guanfacine-dependent increase in delivery of tubular fluid to the loop
of Henle, where furosemide exerts its natriuretic and kaliuretic action.
The natriuretic effect of clonidine, as adjunct to diuretics, is maximal during CCl4 weeks 11
and 12, is accompanied by transient improvement of renal function and decrease in catechol-
amine release, but is followed by severe deterioration of GFR over the following weeks of treat-
ment (Tables 1 and 3; Figs 2 and 3). This is different from the ephemeral increase in urine flow
and sodium excretion rate due to diuretics only, which apparently prompts early and uncon-
trolled stimulation of adrenergic function and secondary aldosteronism (Tables 1 and 3; Figs 3
and 4).
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Clonidine’s and guanfacine’s beneficial effects, transient the former and later the latter, may
have the following reasons. First, clonidine exerts its adrenolytic effects earlier than the oral
prodrug of guanfacine (Table 3, Fig 3) because of the need of metabolic activation of the latter,
metabolic activation that might be slowed down in a setting of liver failure. Second, aspecific
α2-adrenergic stimulation by clonidine may elicit some potential anti-natriuretic forces that are
the consequence of stimulation of NO synthesis [14–17]. Third and last, it was demonstrated
that α2A-receptor stimulation (by guanfacine or analogues) leads to direct tubular diuretic
effects [18].
So far, only clonidine has been tested in order to ameliorate the effects of diuretics in
patients with advanced cirrhosis and ascites. And these attempts were successful [10– 12]. It is
conceivable that, in patients with decompensated cirrhosis, as well as in our model of experi-
mental ascites, beneficial diuretic effects of clonidine might be short-lived. And, in this proba-
ble case, oral prodrug of guanfacine would be worth being tried instead of clonidine, once
suitable guanfacine’s dosage and schedule is clearly established in patients with decompensated
cirrhosis.
In conclusion, this study represents the first successful use of α2A-adrenoceptor agonists in
order to increase the diuretic effects of furosemide and anti-aldosterone drugs in the setting of
experimental advanced cirrhosis with ascites. No previous clinical or experimental study has
ever been performed with this aim. Moreover, we described a suitable experimental model of
diuretic-resistant ascites in cirrhotic rats. This model may be useful for further pathophysiolog-
ical or pharmacological studies. Future efforts to arrange dosage and administration schedule
of oral prodrugs of guanfacine for the treatment of cirrhotic patients with ascites seem now
worthwhile.
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